Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)

<i>Background and Objectives</i>: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed/refractory multiple myeloma (RRMM). <i>Materials and Methods</i>: This study evaluates the real-world effectiveness and safety of IRd in Croat...

Полное описание

Библиографические подробности

Главные авторы:	Josip Batinić, Barbara Dreta, Goran Rinčić, Antonia Mrdeža, Karla Mišura Jakobac, Delfa Radić Krišto, Milan Vujčić, Mario Piršić, Željko Jonjić, Vlatka Periša, Jasminka Sinčić Petričević, Božena Coha, Hrvoje Holik, Toni Valković, Marija Stanić, Ivan Krečak, Ante Stojanović, Domagoj Sajfert, Sandra Bašić-Kinda
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2024-11-01
Серии:	Medicina
Предметы:	ixazomib lenalidomide multiple myeloma relapsed/refractory retrospective study
Online-ссылка:	https://www.mdpi.com/1648-9144/60/11/1905
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!